logo

TAK

Takeda Pharmaceutical·NYSE
--
--(--)
--
--(--)
4.39 / 10
Netural

TAK's fundamental score is 4.39/10, indicating a mixed quality. Key positives include a Days Sales Outstanding of 54.13 (Group 1, 3/3 points) and a Cost of Sales Ratio of 34.49% (Group 1, 3/3 points), both historically linked to modest returns. However, a PB-ROE of -0.67 places it in Group 1 with only 1 point, signaling a weakness in valuation versus profitability. Overall, the fundamentals lean neutral, warranting prudent investment.

Fundamental(4.39)SentimentTechnical

Analysis Checks(9/10)

Revenue-MV
Value0.90
Score3/3
Weight19.63%
1M Return11.66%
Days sales outstanding
Value54.13
Score3/3
Weight1.71%
1M Return1.30%
Profit-MV
Value5.59
Score3/3
Weight19.67%
1M Return12.21%
PB-ROE
Value-0.67
Score1/3
Weight18.33%
1M Return12.11%
Income tax / Total profit (%)
Value38.23
Score2/3
Weight3.21%
1M Return2.06%
Interest coverage ratio (EBIT / Interest expense) (%)
Value2.07
Score2/3
Weight-0.82%
1M Return-0.66%
Operating revenue (YoY growth rate %)
Value7.45
Score2/3
Weight0.71%
1M Return0.55%
Cost of sales ratio (%)
Value34.49
Score3/3
Weight1.00%
1M Return0.72%
Asset-MV
Value1.33
Score2/3
Weight22.33%
1M Return11.67%
Cash-MV
Value0.86
Score2/3
Weight14.24%
1M Return7.70%
Is TAK undervalued or overvalued?
  • TAK scores 4.39/10 on fundamentals and holds a Fair valuation at present. Backed by its 2.96% ROE, 2.54% net margin, 74.69 P/E ratio, 1.16 P/B ratio, and -39.04% earnings growth, these metrics solidify its Netural investment rating.